Application Of MR/US Fusion Guided Prostate Targeted Biopsy Based On PIRADS 2.0 Scoring System In The Diagnosis Of Prostate Cancer

Objective By comparing with systematic biopsy of prostate,to analyze the diagnostic effects of MR/US fusion targeted biopsy of prostate which is based on PIRADS 2.0,and to analyze the diagnostic effects of that when the PSA is under 10 ng/mL.At the same time,to analyze the diagnostic effects of PIRADS 2.0 for clinically significant prostate cancer.Methods A total of 357 patients who underwent fusion biopsy and systematic biopsy in Zhejiang Provincial People’s Hospital from May 2018.to April 2020 were collected.Then,we compared the positive detection rate of these two biopsy methods.And,we analyzed data of PIRADS 2.0 for clinically significant prostate cancer.Also,the biopsy results of these two methods were compared.Results Compared with systematic biopsy,MR/US fusion targeted biopsy guided by PIRADS 2.0 has a higher positive detection rate and positive rate of puncture needles(P<0.05).When the PSA is under 10 ng/mL,MR/US fusion targeted biopsy guided by PIRADS 2.0 has a higher positive detection rate,and can discover more clinically significant prostate cancer(P<0.05).Conclusion MR/US fusion targeted biopsy guided by PIRADS 2.0 has high biopsy accuracy in prostate cancer.MR/US fusion targeted biopsy guided by PIRADS 2.0 with systematic biopsy can further improve the detection efficiency of prostate cancer.When the PSA is under 10 ng/mL,MR/US fusion targeted biopsy guided by PIRADS 2.0 has a higher positive detection rate.PIRADS 2.0 plays an important role in guiding the diagnosis of clinically significant prostate cancer.